Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil
Aida Mohammadkhani, Morgan H. James, Caroline B. Pantazis, et al.
Brain Research (2019) Vol. 1731, pp. 146461-146461
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

The Orexin/Hypocretin System, the Peptidergic Regulator of Vigilance, Orchestrates Adaptation to Stress
Miklós Jászberényi, Balázs Thurzó, Zsolt Bagosi, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 448-448
Open Access | Times Cited: 22
Sex Differences in Demand for Highly Palatable Foods: Role of the Orexin System
Linnea R. Freeman, Brandon S. Bentzley, Morgan H. James, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 1, pp. 54-63
Open Access | Times Cited: 59
Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?
Morgan H. James, Jennifer E. Fragale, R. Nisha Aurora, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 5, pp. 717-719
Open Access | Times Cited: 51
Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors
F. Woodward Hopf
Neuropharmacology (2020) Vol. 168, pp. 108013-108013
Open Access | Times Cited: 50
Sleep dysregulation in binge eating disorder and “food addiction”: the orexin (hypocretin) system as a potential neurobiological link
Jacqueline B. Mehr, Deborah Mitchison, Hannah E. Bowrey, et al.
Neuropsychopharmacology (2021) Vol. 46, Iss. 12, pp. 2051-2061
Open Access | Times Cited: 46
Ventral pallidal regulation of motivated behaviors and reinforcement
Carina Soares‐Cunha, Jasper A. Heinsbroek
Frontiers in Neural Circuits (2023) Vol. 17
Open Access | Times Cited: 20
Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Marc Ten-Blanco, África Flores, Luigia Cristino, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101066-101066
Open Access | Times Cited: 19
Ventral pallidum cellular and pathway specificity in drug seeking
Yonatan M. Kupchik, Asheeta A. Prasad
Neuroscience & Biobehavioral Reviews (2021) Vol. 131, pp. 373-386
Closed Access | Times Cited: 34
Understanding the Role of Orexin Neuropeptides in Drug Addiction: Preclinical Studies and Translational Value
Alessandra Matzeu, Rémi Martin‐Fardon
Frontiers in Behavioral Neuroscience (2022) Vol. 15
Open Access | Times Cited: 26
Orexin receptors: possible therapeutic targets for psychiatric disorders
Shigeyuki Chaki
Psychopharmacology (2025)
Closed Access
Demand for fentanyl becomes inelastic following extended access to fentanyl vapor self-administration
Sam A. McConnell, Adam J. Brandner, Brandon A. Blank, et al.
Neuropharmacology (2020) Vol. 182, pp. 108355-108355
Open Access | Times Cited: 32
The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System
Jennifer E. Fragale, Morgan H. James, Jorge A. Avila, et al.
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 117-127
Open Access | Times Cited: 29
The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse
Morgan H. James, Jennifer E. Fragale, Shayna L. O’Connor, et al.
Neuropharmacology (2020) Vol. 183, pp. 108359-108359
Open Access | Times Cited: 29
New directions in modelling dysregulated reward seeking for food and drugs
Robyn M. Brown, Christopher V. Dayas, Morgan H. James, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 1037-1048
Open Access | Times Cited: 23
Oxytocin and orexin systems bidirectionally regulate the ability of opioid cues to bias reward seeking
Giuseppe Giannotti, Francesca Mottarlini, Jasper A. Heinsbroek, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 17
Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats
Jessica M. Illenberger, Francisco J. Flores‐Ramirez, Alessandra Matzeu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 9
Orexin-mediated Motivated Arousal and Reward Seeking.
Theresa E. Bjorness, Robert Greene
Peptides (2024) Vol. 180, pp. 171280-171280
Closed Access | Times Cited: 3
Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats
Alessandra Matzeu, Rémi Martin‐Fardon
Neuropharmacology (2019) Vol. 164, pp. 107906-107906
Open Access | Times Cited: 28
The orexin-1 receptor antagonist SB-334867 reduces motivation, but not inhibitory control, in a rat stop signal task
Joost Wiskerke, Morgan H. James, Gary Aston‐Jones
Brain Research (2019) Vol. 1731, pp. 146222-146222
Open Access | Times Cited: 26
Orexin type-1 receptor inhibition in the rat lateral paragigantocellularis nucleus attenuates development of morphine dependence
Zahra Rezaei, Masoumeh Kourosh‐Arami, Hossein Azizi, et al.
Neuroscience Letters (2020) Vol. 724, pp. 134875-134875
Closed Access | Times Cited: 22
Targeting the Orexin System for Prescription Opioid Use Disorder
Alessandra Matzeu, Rémi Martin‐Fardon
Brain Sciences (2020) Vol. 10, Iss. 4, pp. 226-226
Open Access | Times Cited: 22
Introduction to the Special Issue: “Making orexin-based therapies for addiction a reality: What are the steps from here?”
Morgan H. James, Gary Aston‐Jones
Brain Research (2020) Vol. 1731, pp. 146665-146665
Open Access | Times Cited: 21
Use of drug purchase tasks in medications development research: orexin system regulation of cocaine and drug demand
Justin C. Strickland, Kevin W. Hatton, Lon R. Hays, et al.
Behavioural Pharmacology (2023) Vol. 34, Iss. 5, pp. 275-286
Open Access | Times Cited: 7
The ventral pallidum and relapse in alcohol seeking
Asheeta A. Prasad, Gavan P. McNally
British Journal of Pharmacology (2020) Vol. 177, Iss. 17, pp. 3855-3864
Open Access | Times Cited: 15
Utility of ‘substance use disorder’ as a heuristic for understanding overeating and obesity
Richard M. O’Connor, Paul J. Kenny
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2022) Vol. 118, pp. 110580-110580
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top